NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

First new drug in over 20 years reduces recurrence in high-risk hormone receptor-positive early breast cancer

By Mindo - 12th Nov 2020

Unrecognizable female gynocologist looking at a patients mammogram at the hospital

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25 per cent in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020. “This is the first time in more than 20 years that we have seen an advance in the adjuvant treatment of this form of breast cancer,” said lead author Prof Stephen Johnston, from the Royal Marsden Hospital NHS Foundation Trust, London, UK. Hormone receptor positive breast cancer remains the commonest form of breast cancer, affecting 70 per cent of patients, with most being diagnosed with early disease. 

“Many of these patients can be cured with currently available treatments: Surgery, radiotherapy, chemotherapy, and hormone treatment. But about 20 per cent have high-risk disease and will develop a recurrence either locally in the breast or elsewhere in the body over the first 10 years of treatment,” he explained.  The international phase 3 monarchE study included 5,637 patients with HR+ HER2- early breast cancer with clinical and/ or pathological risk factors putting them at high-risk for relapse. After completing their primary treatment they were randomised on an open-label basis to abemaciclib (150mg twice daily for two years) plus endocrine therapy or endocrine therapy alone. “We found a 25 per cent reduction in recurrence of cancer with the first two years when abemaciclib was added to hormone therapy compared to hormone therapy alone,” reported Prof Johnston. During this time 11.3 per cent of patients in the control group had a relapse of their cancer compared to 7.8 per cent of those in the abemaciclib group, an absolute difference of 3.5 per cent, which translates to a 25.3 per cent reduction in risk. Most of the reductions occurred in sites of distant metastases, especially to liver and bone.

Leave a Reply

Latest Issue
medical independent 5th December
The Medical Independent 5th December 2023

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read